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Constipation as the Presenting
Symptom in De Novo Multiple
Endocrine Neoplasia Type 2B
ABBREVIATIONS. MEN 2, multiple endocrine neoplasia type 2;
MTC, medullary thyroid carcinoma; PCR, polymerase chain reac-
tion; IND B, intestinal neuronal dysplasia type B.
Multiple endocrine neoplasia type 2 (MEN 2)comprises three clinically distinct domi-nantly inherited neuroendocrine cancer
syndromes: MEN 2A, MEN 2B, and familial medul-
lary thyroid carcinoma, which share medullary thy-
roid carcinoma (MTC) as part of the disease spec-
trum.1 MEN 2A patients are characterized by the
additional occurrence of pheochromocytoma and/or
parathyroid hyperplasia. MEN 2B patients also have
pheochromocytomas and, very rarely, parathyroid
hyperplasia; in addition, they have mucosal neuro-
mas, mainly of the buccal mucosa and tongue, gan-
glioneuromatosis of the gastrointestinal tract, skele-
tal and ophthalmologic abnormalities, and a
Marfanoid habitus2 (Table 1). All MEN 2 syndromes
are caused by missense mutations in different areas
of the RET proto-oncogene,3–5 which encodes a recep-
tor tyrosine kinase, for which glial cell-line derived
neurotrophic factor and neurturin are the ligands.6–8
A single, identical point mutation in the catalytic
core of the RET tyrosine kinase domain (codon
918Met3Thr) has been found in 94% of inherited and de
novo cases of MEN 2B, which makes this disorder
well-suited for genetic testing.9 Because of this and
because 50% of MEN 2B cases present de novo, it is
important to be aware of possible presenting symp-
toms in combination with the typical features of
MEN 2B patients. Very rarely, patients with typical
MEN 2B features do not have RET codon 918 (exon
16) mutations.9–11 Those cases are most probably
caused by mutations elsewhere in the RET gene, eg,
at codon 883 of RET exon 15.12
In this report, we present a case of a girl with
dysmorphic features, chronic constipation, and ab-
normal histology of the enteric nervous system in
early childhood. Sixteen years later, she presented
with MTC and was found to harbor a de novo RET
mutation, characteristic of MEN 2B.
MATERIALS AND METHODS
Histology and Immunohistochemistry
Five-micron sections of paraffin-embedded tissue (resected co-
lon and MTC) were deparaffinized. Hematoxylin and eosin and
sirius red staining (colon) were performed according to standard
methods. For immunohistochemistry, sections were incubated for
30 minutes at room temperature with antibodies to calcitonin
(1:900, Dako, Glostrup, Denmark) and thyroglobulin (1:2500,
Dako) for the MTC, and PGP9.5 (1:1000, Biogenesis, New Fields,
UK) and S100 (1:2500, Dako) for the colon. A microwave antigen
retrieval method was used followed by overnight incubation at
4°C for antibodies to RET (1:3000, Dako), for the MTC. Then,
sections were washed and a biotinylated goat-anti-multilink (1:50,
Klinipath Biogenex, Uden, The Netherlands) with 2% normal hu-
man serum and 2% normal goat serum (Dako) was added for 30
minutes, followed by the avidin-biotin-complex (1:50, Klinipath
Biogenex) for 30 minutes. Sections were developed with diamino-
benzidine tetrahydrochlorate (Fluka, Neu-Ulm, Germany) with
0.3% H2O2 for 7 minutes, counterstained, dehydrated, and
mounted.
Mutational Analysis
Lymphocyte DNA was isolated according to standard proce-
dures from the index patient, from both parents, and from both
siblings. Polymerase chain reaction (PCR) was carried out as pre-
viously described.5 The PCR products were purified in low-melt-
ing point agarose, isolated (Sephaglas BandPrep kit, Pharmacia,
Uppsala, Sweden) and digested for 1 hour using 2U FokI (Boehr-
inger, Mannheim, Germany) in the restriction buffer recom-
mended by the manufacturer. The samples were run in a 1%
normal agarose/2% low-melting point agarose gel.
CASE REPORT
A 2-year-old child of nonconsanguineous parents came to med-
ical attention because of severe growth retardation without
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TABLE 1. Features of MEN 2B
Facial abnormalities
Thickened and everted upper eyelids
Prominent eyebrows
Neuromas on eyelids and conjunctiva
Thickened corneal nerves
Elongated face
Thickened lips
Neuromas of buccal mucosa, tongue, and palate
Marfanoid habitus/musculoskeletal manifestations
Tall stature
High-arched palate
Long extremities
Kyphoscoliosis or lordosis
Joint laxity
Pes cavus
Pectus excavatum
Slipped capital femoral epiphysis
Gastrointestinal manifestations
Abdominal distension
Feeding problems
Dysphagia
Vomiting
Chronic constipation
Paradoxal diarrhea
Megacolon
Ganglioneuromatosis
Tumors
C-cell hyperplasia/medullary thyroid carcinoma
Pheochromocytoma
Parathyroid hyperplasia
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catch-up growth and presumed psychomotor retardation, which
was not proven at subsequent analysis. At physical examination
she was growth-retarded (length well below P3) and presented
with dysmorphic features including hypertelorism, a broad fore-
head and mouth, a short neck, high-arched palate, and pectus
excavatus. Radiography of the skeleton revealed vertebral abnor-
malities: occipitalization of C1, a hypoplastic C2, block vertebrae
C2 and C3, and scoliosis. Skeletal age was delayed.
During evaluation she was found to have severe chronic con-
stipation and paradoxal diarrhea. Radiographically, the transverse
colon was dilated, the splenic flexure seemed stenotic, and the
distal colon was collapsed. Because Hirschsprung disease was
suspected, a biopsy was taken that showed the same histologic
features as the later bowel resection (see below). At subsequent
laparotomy the radiographic findings were confirmed but no ste-
nosis could be located. The splenic flexure was removed for patho-
logic examination. There was an increase in the number of gan-
glion cells, both in the submucous and myenteric plexus as well as
an increase in nerve fibers in submucosa and mucosa, part of
which were acetylcholinesterase-reactive. The ganglion cells were
of normal size, but there were no ectopic ganglion cells in the
lamina propria or muscularis mucosae. As aganglionosis of the
distal colon had been excluded, continuity was restored. The
initial pathologic diagnosis was intestinal neuronal dysplasia of
the colon. At review, many years later, this was changed to gan-
glioneuromatosis (Fig 1).
In subsequent years she was seen for the analysis of persistent
diarrhea and because of neurogenic bladder dysfunction and ure-
teral reflux. At the age of 18 years a swelling of the thyroid region
was noted, and during physical examination prominent lips and
tongue neuromas were noticed for the first time. Around that time
DNA analysis for RET mutations was performed for both parents
and the three children. A codon 918 (exon 16) mutation was found
in the index patient, but not in the DNA of parents and siblings
(Fig 2). Subsequent investigations revealed an unevenly enlarged
thyroid with calcifications, tracheal compression, and markedly
elevated serum calcitonin, carcinoembryonic antigen, and CA125.
A total thyroidectomy was performed, and MTC was found in the
resected gland (Fig 3). A single metastasis was present in a re-
gional lymph node. Calcitonin and carcino-embryonic antigen
levels returned to control levels after the operation. Recently, 2
years postoperatively, she was found to have a positive somatosta-
tin scan in the neck and mediastinal region and a raised calcitonin
level was found after pentagastrin stimulation, both indicating
that MTC metastasis may be present. Cytology of neck lymph
node was consistent with MTC metastasis.
Before and after thyroidectomy, urinary vanillylmandelic acid
excretion was repeatedly around the upper limit of normal, but
the meta-iodobenzylguanidine scan did not show increased up-
take in the adrenals. Furthermore, glucagon provocation showed
a normal response. At present, there is no indication for the
presence of a pheochromocytoma.
DISCUSSION
This patient with a de novo RET codon 918Met3Thr
mutation, leading to the MEN 2B syndrome, origi-
nally presented with chronic constipation, paradoxal
diarrhea, and histologic abnormalities of the enteric
nervous system in rectal and colonic biopsies. MEN
2B is a rare autosomal dominant disorder of which
MTC is the most serious and potentially lethal com-
plication. MTCs in MEN 2B are known to run an
aggressive course, as compared with MTCs in MEN
2A, and metastatic MTCs may be found in children
younger than age 5.13 This may be related to the site
of the RET mutation, as sporadic MTCs with an
identical RET codon 918 mutation also follow an
aggressive clinical course with earlier tumor recur-
rence, higher frequency of metastases, and decreased
survival rate.14–16 Early detection of individuals at
risk for MEN 2B allows prophylactic thyroidectomy
to be carried out before metastatic disease occurs.17–19
This screening, however, is hampered by the fact that
at least 50% of MEN 2B cases represent de novo
mutations.20 For such patients, presenting symptoms
Fig 1. Resected colon segment showing the hyperplasia of the
submucous plexus with multiple ganglion cells and broad nerve
fibers, typical of ganglioneuromatosis (hematoxylin-eosin, 340).
Fig 2. Restriction patterns of PCR products of exon 16 of RET
with FokI. The MEN 2B mutation (T27533C) eliminates a FokI
restriction site. The undigested (u) and the digested (d) PCR
products of constitutive DNA from a control individual (No. 1),
from the index patient (No. 2) and from a known MEN 2B patient
(No. 3) are shown. The index patient and the MEN 2B patient
show the same digestion pattern, caused by the same mutation.
Fig 3. Medullary thyroid carcinoma with a solid proliferation or
round to polygonal cells with granular amphophilic cytoplasm
with medium-sized nuclei. Between the tumor cells is highly
vascularized stroma with collagen bands and amyloid depositions
(hematoxylin-eosin, 340).
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should lead to clinical suspicion prompting genetic
testing.
Many studies have indicated the early occurrence of
clinical gastrointestinal symptoms in MEN 2B patients,
including difficulty in feeding, dysphagia, vomiting,
constipation, diarrhea, borborygmus, intermittent ab-
dominal pain, and occasional malabsorption.21–24 Of
these, chronic constipation and diarrhea are the most
commonly observed. However, such clinical symp-
toms are common in the general pediatric age group,
with a multitude of etiologic and pathogenetic factors
involved. Therefore, additional clinical data are re-
quired. In MEN 2B, several radiographic abnormalities
may be found: disturbed motility and segmental dila-
tation of the esophagus, gastroesophageal reflux, dis-
tention of the stomach, segmental dilatation of the
small bowel, abnormal haustral pattern of the colon,
and megacolon, which is the most frequent abnormal-
ity.21,25 Although the differential diagnosis of megaco-
lon includes many disorders (Table 1), Hirschsprung
disease is usually suspected strongly.
Intestinal mucosal biopsy yields important infor-
mation about the intestinal innervation pattern and
allows the differentiation between Hirschsprung dis-
ease and ganglioneuromatosis. In Hirschsprung dis-
ease a bowel segment of variable length is agangli-
onic and presents an increase in cholinergic nerve
fibers. The neighboring bowel segment is hypogan-
glionic. Ganglioneuromatosis displays an increase in
ganglion cells, supportive cells, and nerve fibers in
all layers of the bowel wall, most notably in the
myenteric plexus.26
Ganglioneuromatosis can involve the entire gas-
trointestinal tract. Recently, a case was presented
with coexistence of ganglioneuromatosis, in the con-
text of MEN 2B with its characteristic RET codon 918
mutation, and a short aganglionic segment, indica-
tive of Hirschsprung disease.27 Intestinal neuronal
dysplasia type B (IND B) has several features resem-
bling ganglioneuromatosis, most importantly sub-
mucosal ganglia with more than six nerve cells.28 No
mention is made about the myenteric plexus.
Whether IND B represents an entity or a secondary
phenomenon has been much debated,29 but is be-
yond the scope of this article.
In our patient, intestinal biopsy was performed
after radiographic detection of a dilated proximal
and a collapsed distal colonic segment. The innerva-
tional abnormalities were initially diagnosed as IND
B. At that time, almost 20 years ago, no facial abnor-
malities were noticed, except a high-arched palate.
However, these abnormalities, most notably neuro-
mas of the tongue, may be discrete in children and
become more prominent in older individuals. As no
genetic testing was available and the Marfanoid fea-
tures (scoliosis, pectus excavatus, high-arched pal-
ate) were not appreciated, it was not until thyroid
enlargement occurred that a diagnosis of MEN 2B
was made. That the sign or symptom leading to the
diagnosis was preceded by a different, at that time
unrecognized, sign or symptom seems characteristic
of this syndrome.24 It is unclear whether the remain-
ing congenital dysmorphic features (broad forehead
and mouth, short neck, and vertebral anomalies) and
the neurogenic bladder dysfunction are coincidental
or related to the MEN 2B phenotype.
CONCLUSION
Our case shows that MEN 2B should be in the
differential diagnosis of chronic constipation in
young children, especially if additional clinical, ra-
diographic, or pathologic findings are indicative of
MEN 2B. In general, mutational analysis of the RET
proto-oncogene is strongly recommended in cases of
histologically abnormal biopsies showing innerva-
tional maldevelopment and in children with one or
more other features of the MEN 2B syndrome, in-
cluding medullary or adrenal tumors (Table 1). This
may lead to (prophylactic) thyroidectomy and/or
prevention of metastatic MTC. Once a diagnosis is
established, genetic counseling should also be of-
fered to other at-risk family members to ascertain
their mutational status.
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Abdominal Lipohypertrophy
Caused by Injections of Growth
Hormone: A Case Report
ABBREVIATIONS. GH, growth hormone; IGF-I, insulin-like
growth factor-I.
Growth hormone (GH) is administered by sub-cutaneous injections. Common complicationshave been limited to bruising, a development
of a hematoma at the injection sites.1,2 However, local
atrophy or dimpling and hypertrophy or lumps have
been observed occasionally. The purpose of this re-
port is to present a boy who developed significant
hypertrophy of the subcutaneous tissue mass at the
local site of GH injections in his abdomen.
CASE REPORT
J. T. was a 12.5-year-old healthy boy with short stature. Linear
growth was noted to decline at 3 years of age. Since then, he
continued to grow slow; in comparison with the growth observed
on his older sibling and peers of the same age group (no docu-
mentation is available). At the time of presentation he was below
two standards deviations from the mean. At the time of his birth
the mother was 32 years old and his father was 48 years of age.
The mother’s stature was 160 cm; the father’s was 173 cm. His
18-year-old brother weighed 3.2 kg at birth. His growth and
development were normal and his stature was 168 cm. There is no
history of consanguinity, short stature, or delayed adolescence in
the family. He was the 2.35-kg, 48.5-cm product of a term gesta-
tion. His mother was G2, P1, and suffers from epilepsy. Medica-
tions used during gestation included Tegretol, Mysoline, and Dya-
zide. The mother was diagnosed with preeclampsia at the last
trimester. The birth was vaginal. Neonatorum was uneventful.
Development milestones included the following: sitting up at 7
months, crawling at 10 months, walking at 19 months, talking at
24 months. In grammar school he required training in communi-
cation skills as well as physical therapy for coordination skills. He
has been able to attend regular school programs, and he is an
average student.
The physical examination revealed a well-nourished, healthy
appearing boy. Stature was 132.2 cm, weight was 27.1 kg, head
circumference was 52.5 cm, arm span was 126 cm, and the upper
to lower ratio was 1.04. (Normal for bone age 0.98 and for chro-
nological age 0.95).3 Secondary sex characteristics were in Tanner’s
stage 1, with a testicular volume of 2 mL laterally. The bone age
was shown to be 10 years old as indicated by the Greulich and
Pyle technique.
Laboratory data revealed: thyroid-stimulating hormone, 3.2
miu/Ml (3.2 pmol/L); thyroxine, 6.8 mg/Dl (87.5 nmol/L). The
insulin-like growth factor-I (IGF-I)-binding protein-3 was 2.2
mg/L (0.05 nmol/L). The L-Dopa stimulation test showed GH
response levels of 9.9, 6.9, and 3.1 ng/Ml at 30, 60, and 90 minutes,
respectively (nL .10 ng/Ml). The complete blood (cell) count,
sedimentation rate, urinalysis, blood urea nitrogen, and serum
electrolytes were all normal.
GH therapy (Protropin) at a dose of 0.05 mg/kg/day was
initiated at 12.5 years of age. It was administered subcutaneous
with a 29-gauge hypodermic needle. The skin was prepared with
alcohol wipes. The linear growth and growth velocity are shown
in Fig 1. The patient’s growth velocity increased significantly
during the GH therapy. Quarterly physical examinations revealed
a progressive increment in abdominal volume that initially was
thought to be a normal abdominal fat increment. At 15 years of age
the configuration and isolated volume of the abdominal morphol-
ogy was judged to be abnormal, consisting of two vertically elon-
gated masses that measured 15 3 12 cm located parallel to the
middle line (Fig 2). The consistency was similar to the rest of the
adjacent subcutaneous tissue and demarcated above the abdomi-
nal musculature. The child’s parents stated that GH has been
exclusively injected under the skin into the abdominal area for the
previous years. The parents were instructed to avoid the abdomen
for the site of injections and to use multiple rotation method. At
the last examination (6 months later) there was ;50% reduction in
the volume of the fat pads. Pubertal development in Tanner’s
stage 2 was noted at 13 years of age; Tanner’s stage 3 at 14 years
of age; and Tanner’s stage 4 at 15.5 years of age.
DISCUSSION
Studies of the lipid metabolism and number, size,
and distribution of fat cell with GH administration
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